Olympus had agreed to sell its microscope unit to private equity firm Bain Capital for $3.1 billion as it speeds up the overhaul of its business portfolio to focus solely on medical technology
The microscope unit, which also manufactures industrial endoscopes and x-ray analyzers, will be transferred to Bain on January 4, subject to antitrust regulatory approvals in Japan and elsewhere.
Olympus stated that the transfer to Bain would benefit the company by allowing it to grow through more agile and flexible decision-making based on market needs.
Bain edged global private equity firms such as Carlyle Group and KKR & Co. for the right to acquire the microscope unit.
Olympus said the transfer to Bain would be in its best interest to allow the business to grow with more agile and flexible decision-making based on market needs.
Bain won over global private equity firms such as Carlyle Group and KKR & Co.
Bain owns flash memory chip maker Kioxia Holdings and is proceeding to a second bidding round for Toshiba.


Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Australia’s December Trade Surplus Expands but Falls Short of Expectations
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Thailand Inflation Remains Negative for 10th Straight Month in January
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



